Alogliptin – the new member of DPP-4 inhibitors class
This review presents data on the efficacy and safety of alogliptin, a new representative of the DPP-4 inhibitors, in adult patients with type2 diabetes mellitus (DM type 2) as monotherapy or in combination with metformin, pioglitazone, glibenclamide and insulin.
| Main Authors: | , |
|---|---|
| Format: | Article |
| Jezik: | English |
| Izdano: |
Endocrinology Research Centre
2014-12-01
|
| Serija: | Ожирение и метаболизм |
| Teme: | |
| Online dostop: | https://www.omet-endojournals.ru/jour/article/view/6818 |